বুলগেরিয়া -
বুলগেরিয় -
Изпълнителна агенция по лекарствата
presucomb 5 mg/5 mg capsules, hard
5 mg/5 mg capsules, hard
বুলগেরিয়া -
বুলগেরিয় -
Изпълнителна агенция по лекарствата
recombinate 1000 iu/10 ml powder and solvent for solution for injection
1000 iu/10 ml powder and solvent for solution for injection
বুলগেরিয়া -
বুলগেরিয় -
Изпълнителна агенция по лекарствата
recombinate 500 iu/10 ml powder and solvent for solution for injection
500 iu/10 ml powder and solvent for solution for injection
বুলগেরিয়া -
বুলগেরিয় -
Изпълнителна агенция по лекарствата
recombinate 250 iu/10 ml powder and solvent for solution for injection
250 iu/10 ml powder and solvent for solution for injection
ইউরোপীয় ইউনিয়ন -
বুলগেরিয় -
EMA (European Medicines Agency)
procoralan
les laboratoires servier - ивабрадин хидрохлорид - angina pectoris; heart failure - Сърдечна терапия - Симптоматично лечение на хронична стабилна ангина пекторис ivabradine е показан за симптоматично лечение на хронична стабилна ангина пекторис в коронарна артерия болест възрастни с нормален синусов ритъм и сърдечната честота ≥ 70 bpm. ivabradine is indicated :in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Лечение на хронична сърдечна недостатъчност ivabradine е посочена в хронична сърдечна недостатъчност nyha ii до iv клас със систолното дисфункция, при пациентите в синусов ритъм и чиито пулс е ≥ 75 bpm, в комбинация със стандартна терапия, включително бета-блокер терапия или Когато терапия с бета-блокер е противопоказано или не понася.
ইউরোপীয় ইউনিয়ন -
বুলগেরিয় -
EMA (European Medicines Agency)
lonsurf
les laboratoires servier - trifluridine, tipiracil хидрохлорид - Колоректални неоплазми - Антинеопластични средства - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.